Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genfit S.A. ADR (NQ: GNFT )

3.660 +0.160 (+4.57%)
Streaming Delayed Price Updated: 3:57 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,440
Open 3.660
Bid (Size) 3.310 (1)
Ask (Size) 3.700 (1)
Prev. Close 3.500
Today's Range 3.490 - 3.660
52wk Range 2.893 - 4.750
Shares Outstanding 38,888,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For April 4, 2024
Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. 
Via Benzinga
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
Via Investor's Business Daily

Performance

YTD
-9.18%
-9.18%
1 Month
+2.52%
+2.52%
3 Month
-3.43%
-3.43%
6 Month
+15.46%
+15.46%
1 Year
-14.33%
-14.33%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
Via Investor's Business Daily
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
Via Benzinga
Analyst Expectations for Genfit's Future
Via Benzinga
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
Via Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
Via Benzinga
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Via Benzinga
Earnings Scheduled For April 13, 2023
Via Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Scheduled For September 28, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
Via Benzinga
BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
Via Benzinga
Analyzing Genfit's Short Interest
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.